An orally administered drug prevents selection for antibiotic-resistant bacteria in the gut during daptomycin therapy

Abstract Background and objectives Previously, we showed proof-of-concept in a mouse model that oral administration of cholestyramine prevented enrichment of daptomycin-resistant Enterococcus faecium in the gastrointestinal (GI) tract during daptomycin therapy. Cholestyramine binds daptomycin in the gut, which removes daptomycin selection pressure and so prevents the enrichment of resistant clones. Here, we investigated two open questions related to this approach: (i) can cholestyramine prevent the enrichment of diverse daptomycin mutations emerging de novo in the gut? and (ii) how does the timing of cholestyramine administration impact its ability to suppress resistance? Methodology Mice with GI E. faecium were treated with daptomycin with or without cholestyramine, and E. faecium was cultured from feces to measure changes in daptomycin susceptibility. A subset of clones was sequenced to investigate the genomic basis of daptomycin resistance. Results Cholestyramine prevented the enrichment of diverse resistance mutations that emerged de novo in daptomycin-treated mice. Whole-genome sequencing revealed that resistance emerged through multiple genetic pathways, with most candidate resistance mutations observed in the clsA gene. In addition, we observed that cholestyramine was most effective when administration started prior to the first dose of daptomycin. However, beginning cholestyramine after the first daptomycin dose reduced the frequency of resistant E. faecium compared to not using cholestyramine at all. Conclusions and implications Cholestyramine prevented the enrichment of diverse daptomycin-resistance mutations in intestinal E. faecium populations during daptomycin treatment, and it is a promising tool for managing the transmission of daptomycin-resistant E. faecium.

[1]  M. Wilcox,et al.  Protecting the Microbiota. , 2021, Journal of Infectious Diseases.

[2]  E. Hansen,et al.  Daptomycin treatment impacts resistance in off-target populations of vancomycin-resistant Enterococcus faecium , 2020, PLoS biology.

[3]  E. Hansen,et al.  An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen , 2020, bioRxiv.

[4]  Heidi Whalen,et al.  Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. , 2019, The Lancet. Infectious diseases.

[5]  Casper W. Berg,et al.  glmmTMB Balances Speed and Flexibility Among Packages for Zero-inflated Generalized Linear Mixed Modeling , 2017, R J..

[6]  Y. Shamoo,et al.  A Novel Mechanism of Resistance Against Antimicrobial Peptides Involves Extracellular Sensing Coupled with Membrane Remodeling Mediated by a Single Protein , 2017 .

[7]  E. Le Chatelier,et al.  Protection of the Human Gut Microbiome From Antibiotics , 2017, bioRxiv.

[8]  D. Fisher,et al.  Advances in prevention and treatment of vancomycin-resistant Enterococcus infection. , 2016, Current opinion in infectious diseases.

[9]  Måns Magnusson,et al.  MultiQC: summarize analysis results for multiple tools and samples in a single report , 2016, Bioinform..

[10]  M. Christner,et al.  Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy. , 2015, International journal of medical microbiology : IJMM.

[11]  A. Wollam,et al.  Whole-Genome Analyses of Enterococcus faecium Isolates with Diverse Daptomycin MICs , 2014, Antimicrobial Agents and Chemotherapy.

[12]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[13]  Scott D. Taylor,et al.  Cardiolipin Prevents Membrane Translocation and Permeabilization by Daptomycin* , 2014, The Journal of Biological Chemistry.

[14]  Y. Shamoo,et al.  Biochemical Characterization of Cardiolipin Synthase Mutations Associated with Daptomycin Resistance in Enterococci , 2012, Antimicrobial Agents and Chemotherapy.

[15]  C. Arias,et al.  Correlation between Mutations in liaFSR of Enterococcus faecium and MIC of Daptomycin: Revisiting Daptomycin Breakpoints , 2012, Antimicrobial Agents and Chemotherapy.

[16]  Nick Colegrave,et al.  The Problem of Auto-Correlation in Parasitology , 2012, PLoS pathogens.

[17]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[18]  Cesar A. Arias,et al.  The rise of the Enterococcus: beyond vancomycin resistance , 2012, Nature Reviews Microbiology.

[19]  G. Weinstock,et al.  Genetic basis for in vivo daptomycin resistance in enterococci. , 2011, The New England journal of medicine.

[20]  N. Socci,et al.  Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. , 2010, The Journal of clinical investigation.

[21]  Paul D. Shaw,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[22]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[23]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[24]  C. Donskey,et al.  P1A Recombinant β-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin , 2009, Antimicrobial Agents and Chemotherapy.

[25]  J. Mckenney,et al.  Safety considerations with gastrointestinally active lipid-lowering drugs. , 2007, The American journal of cardiology.

[26]  Douglas M. Bates,et al.  LINEAR AND NONLINEAR MIXED-EFFECTS MODELS , 1998 .

[27]  K J Ryan,et al.  Antimicrobial Susceptibility Testing , 2016, Advances in Experimental Medicine and Biology.

[28]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[29]  I. Aursnes Drugs that affect lipid metabolism , 2007 .

[30]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .